The infection
releases tumor antigens in a way that jump - starts the immune response.»
Not exact matches
Many
tumors release cells with distinctive
antigens on their surfaces, and affinity - based techniques can pull these cells out of the blood sample relatively easily.
Lloyd Old, Thierry Boon, and colleagues develop the TNF
release assay for mouse systems in which
release of TNF by T cells could be used to assess specific T cell recognition, facilitating the cloning of human
tumor antigens.
There, they will be exposed to
tumor antigens released from dying glioma cells through TK + valacyclovir - induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells.
Instead of targeting specific
tumor antigens, this approach relies on endogenous
antigens (including neoantigens)
released during
tumor lysis by treatments such as chemotherapy or local radiation.
We believe that when G100 is administered with mechanisms that kill, or lyse,
tumor cells (such as radiation), it may cause dendritic cells near the lysed
tumor to activate and capture the wide range of
released endogenous
tumor antigens.